US FDA panel meeting on Avandia to include comparative safety of Actos
This article was originally published in Scrip
Executive Summary
A US FDA advisory panel meeting next month on the cardiovascular safety of GlaxoSmithKline's diabetes agent Avandia (rosiglitazone) will include an agency meta-analysis of the safety of Takeda's competing thiazolidinedione Actos (pioglitazone).